Name: TerzaPower (60mg)
Brand: TrueMed Ukraine

Dual GLP-1/GIP receptor agonist for comprehensive weight management, metabolic balance, and glycemic control

Doctor Cosmetologist Dealer

What is TerzaPower ?

TerzaPower (tirzepatide) is the first-in-class dual agonist of GLP-1 and GIP receptors, simultaneously activating two key metabolic pathways to achieve clinically significant weight reduction and improved glycemic control — results unattainable with monotherapy.

✓Dual GLP-1 & GIP receptor activation
✓CNS-mediated appetite suppression
✓Gastric slowing — prolonged satiety
✓Enhanced pancreatic insulin secretion
✓Reduced glucagon & hepatic glucose output
✓Lipolysis activation & improved insulin sensitivity

Intended exclusively for use under the supervision of a qualified specialist.

Meet TerzaPower

A next-generation revolutionary molecule for deep metabolic restoration

TerzaPower is tirzepatide in a format adapted for clinical and wellness practice. By combining GLP-1 and GIP receptor activation, it provides a synergistic effect on appetite, glucose metabolism, and fat metabolism — results unachievable with monotherapy.

Suitable for integration into comprehensive weight management programs, metabolic rehabilitation protocols, and preventive medicine.

Key effects of TerzaPower

Comprehensive metabolic impact through a dual mechanism of action

Weight loss up to 20%+

Glycemic control

Appetite reduction

Lipid profile improvement

Cardiometabolic protection

Insulin sensitivity

Blood pressure reduction

Sleep quality & energy levels

Why TerzaPower?

How does TerzaPower differ from other GLP-1 agonists?

Unlike GLP-1 monotherapy (semaglutide, liraglutide), TerzaPower simultaneously activates GLP-1 and GIP receptors — two independent metabolic pathways. This provides greater weight loss efficacy (up to 22.5% in clinical trials) and better glycemic control compared to monotherapy.

Which patients is TerzaPower suitable for?

TerzaPower is suitable for adult patients with:

Obesity or overweight (BMI ≥ 27) with comorbid metabolic disorders
Type 2 diabetes requiring improved glycemic control
Elevated cardiometabolic risk
Metabolic syndrome as part of comprehensive therapy

Prescribing is exclusively by physician indication.

What clinical studies confirm efficacy?

SURMOUNT-1 — weight loss up to 22.5% over 72 weeks in obese patients without diabetes (15 mg dose).

SURPASS-2 — tirzepatide's superiority over semaglutide 1 mg in reducing HbA1c and body weight in type 2 diabetes patients.

SURMOUNT-4 — maintenance of results with long-term use; discontinuation leads to weight regain.

How to integrate TerzaPower into a wellness program?

TerzaPower is most effective in combination with:

Individual dietary protocol
Regular physical activity
Monitoring of metabolic indicators (glucose, lipids, BP)
Psychological support for changing eating behaviour

Titration protocol and duration of use are determined individually by the physician.

What are the side effects and contraindications?

Most common side effects (primarily during titration): nausea, vomiting, diarrhoea, decreased appetite — generally transient and managed by titration pace.

Contraindications: personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy. Full list in the product information leaflet.

SURMOUNT-1

Weight loss up to 22.5% over 72 weeks in obese patients (15 mg dose)

SURPASS-2

Superiority over semaglutide 1 mg in reducing HbA1c and body weight in type 2 diabetes

Dual mechanism

The only molecule with dual GLP-1/GIP agonism for maximum metabolic effect

FDA & EMA

FDA-approved (Mounjaro/Zepbound) for obesity and type 2 diabetes treatment

Compliance with standards

FDA Approved

EMA Reviewed

GMP

ISO 9001

How TerzaPower works

Dual activation of GLP-1 and GIP receptors in the GI tract and brain
Appetite and hunger reduction through central CNS mechanisms
Slowing of gastric emptying — prolonged satiety
Improvement of glucose-dependent insulin secretion by pancreatic beta cells
Reduction of glucagon production and suppression of hepatic gluconeogenesis
Activation of adipose tissue lipolysis and increased peripheral insulin sensitivity